Inflammatory bowel disease Flashcards
1
Q
What is ulcerative colitis and where does it affect?
A
- UC is a relapsing + remitting inflammatory disorder of colonic mucosa
- may affect:
- just the rectum (proctitis ~30%)
- extend to involve part of colon (left-sided colitis, in ~40%)
- entire colon (pancolitis, in ~30%)
- ‘never’ spreads proximal to ileocaecal valve (except for backwash ileus)
2
Q
What are the main risk factors for UC?
A
- FHx of IBD → between 10-20% of pts have at least 1 family member w/ IBD
- HLA-B27 → identified in most pts w/ UC
- Infection → up to 50% of relapses of colitis are associated w/ enteritis due to recognised pathogens
3
Q
What are the clinical features of UC?
A
- Acute attacks alternate w/ asymptomatic intervals
- Chronically active course (>2 relapses/year)
- Incomplete remission despite adequate treatment
- Diarrhoea w/ macroscopic visible blood + mucus
- Abdominal pain, tenesmus
- Tenderness (left lower abdo)
- Extra-intestinal → anaemia, fever, weight loss, malaise, arthritis, sacroilitis, erythema nodosum, pyoderma gangraenosum, eye symptoms
- Concomitant disease → PSC, amyloidosis, liver disease, ank spond
4
Q
What is the pathophysiology of UC?
A
- microscopically, UC usually involves ONLY THE MUCOSA
- formation of crypt abscesses
- coexisting depletion of goblet cell mucin
- ulcerated areas soon covered by granulation tissue
- undermining mucosa of XS of granulation tissue form polypoidal mucosal excrescences known as polyps or pseudopolyps
5
Q
What are the investigations for UC?
A
- Stool studies → faecal calprotectin
- Bloods → FBC, LFTs, ESR, CRP
- AXR → toxic megacolon
- Flexi sigmoidoscopy
- Colonoscopy + biopsies → widespread ulceration with preservation of adjacent mucosa which has appearance of polyps
6
Q
How do you assess severity of a UC attack?
A
7
Q
What is the management of UC?
A
- Mild attack → mesalazine (5-ASA) for remission-induction/maintenance; given PR for distal disease or PO For extensive disease, combine PO + PR if flare
- Moderate attack → if 4-6 motions/day but otherwise well, induce remission w/ oral prednisolone 40mg/d for 1 wk, then taper by 5mg/week over 7 weeks → then maintain on 5-ASA
- Severe attack → admit for: IV hydration/electrolyte replacement; IV steroids (hydrocortisone or methylprednisolone); rectal steroids (hydrocortisone); thromboembolism prophylaxis
8
Q
What are the complications of UC?
A
- Toxic megacolon → colon begins to widen (dilate), may be due to problems with muscle contraction or digestive reflexes; rare complication + occurs in 2.5% of those with UC
- Colonic adenocarcinoma → develops in 3-5% pts w/ UC; risk increases with duration of disease
9
Q
What is Crohn’s disease?
A
- chronic inflammatory disease
- characterised by transmural granulomatous inflammation
- affecting any part of gut from mouth to anus (esp term ileum 70%)
- unlike UC, there is unaffected bowel between areas of active disease (skip lesions)
- age 15-40 or 60-80yrs → bimodal age distribution for onset
10
Q
What are the clinical features of Crohn’s disease?
A
- diarrhoea → usually non-bloody
- weight loss → Crohn’s > UC
- systemic features → fatigue, fever, malaise, anorexia
- abdo tenderness/mass → RIF
- perianal abscess/fistulae/skin tags
- mouth ulcers
- clubbing
11
Q
What is the pathophysiology of Crohn’s?
A
- initial lesion starts as an inflammatory infiltrate around intestinal crypts
- subsequently develops into ulceration of the superficial mucosa
- inflammation progresses to involve deeper layers + forms non-caseating granulomas
- granulomas involve ALL layers of intestinal wall + mesentry + regional lymph nodes
- finding of these granulomas is highly suggestive of CD, yet absence does not exclude diagnosis
12
Q
What investigations are done for Crohn’s?
A
- stool MC+S → faecal calprotectin
- bloods → FBC, iron studies, B12, folate, CRP, ESR
- colonscopy + biopsy → cobble-stone appearance, histology to diagnose
- CT/MRI → localises disease + diagnoses complications
13
Q
What is the management of Crohn’s in terms of inducing remission?
A
- conventional steroids (prednisolone, methylpred, IV hydrocortisone) to induce remission in people w/ a 1st presentation or single inflammatory exacerbation of CD in a 12 month period
- in ppl w/ 1+ of distal ileal, ileocaecal or right-sided colonic disease who decline, cannot tolerate or in whom a conventional steroid is contraindicated → consider budesonide
- consider adding azathioprine or mercaptopurine to conventional steroid or budesonide to induce remission in CD if:
- 2+ inflammatory exacerbations in a 12-month period, OR
- steroid dose cannot be tapered
14
Q
What is the management of Crohn’s in terms of maintaining remission?
A
- offer azathioprine or mercaptopurine as monotherapy to maintain remission
- consider methotrexate to maintain remission only in people who
- needed methotrexate to induce remission, OR
- have tried but did not tolerate azathioprine or mercaptopurine
15
Q
What are complications of Crohn’s?
A
- intestinal obstruction → due to bowel wall thickening - presents w/ abdo pain, N+V, abdo distension + dilated bowel loops on AXR
- malignancy → overall inc risk of cancer + inc risk of colon adenocarcinoma
- kidney stones → develops in pt w/ severe disease due to inc absorption of oxalate, poor digestion of fats, acidosis + dehydration